Skip to main navigation Skip to main content Skip to page footer

Γαστρεντερολογικη Κλινική

ΔΗΜΟΣΙΕΥΣΕΙΣ

  Ο κατάλογος των 180 ερευνητικών εργασιών που δημοσιεύθηκαν στη διεθνή βιβλιογραφία με συμμετοχή μελών της Κλινικής κατά την περίοδο από 01/05/2013 μέχρι 30/06/2019 φαίνεται παρακάτω. Τα μέλη της Κλινικής που συμμετέχουν στην κάθε δημοσίευση φαίνονται με τονισμένα γράμματα.

Οι δημοσιεύσεις παρατίθενται ανάλογα με το συντελεστή απήχησης (Impact Factor, IF) του περιοδικού και το έτος δημοσίευσης.

O συνολικός IF των παρακάτω εργασιών είναι: 847.608

  1. Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, Mensa FJ. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment.N Engl J Med. 2017 Oct 12;377(15):1448-1455. IF: 79.258
  2. Tsochatzis EA, Papatheodoridis GV. Case 21-2016: A Man in an Unresponsive State.N Engl J Med. 2016 Oct 27;375(17):1697. (Letter to the editor). IF:79.258
  3. Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.Lancet Infect Dis. 2019 Mar;19(3):275-286. I.F.: 25.148
  4. Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL; Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Study 149 Investigators. Gastroenterology. 2016 Jan;150(1):134-144. IF: 20.773
  5. Rivera-Nieves J, Bamias G. Anti-Interleukin-12/23 Blockade Offers Novel Therapeutic Opportunities for the "Difficult" Patient with Crohn's Disease.Gastroenterology. 2016 May;150(5):1237-1239. (Selected summary). IF: 20.773
  6. Bamias G, Dinarello CA, Rivera-Nieves J.Innate cytokines dictate the fate of acute intestinal inflammation.Gastroenterology. 2015 Jan;148(1):248-50. (Selected summary). IF: 20.773
  7. Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A.Telbivudine improves renal function in patients with chronic hepatitis B.Gastroenterology. 2014 Jan;146(1):138-146. IF: 20.773
  8. Ek WE, Reznichenko A, Ripke S, Niesler B, Zucchelli M, Rivera NV, Schmidt PT, Pedersen NL, Magnusson P, Talley NJ, Holliday EG, Houghton L, Gazouli M, KaramanolisG, Rappold G, Burwinkel B, Surowy H, Rafter J, Assadi G, Li L, Papadaki E, Gambaccini D, Marchi S, Colucci R, Blandizzi C, Barbaro R, Karling P, Walter S, Ohlsson B, Tornblom H, Bresso F, Andreasson A, Dlugosz A, Simren M, Agreus L, Lindberg G, Boeckxstaens G, Bellini M, Stanghellini V, Barbara G, Daly MJ, Camilleri M, Wouters MM, D'Amato M. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut. 2015 Nov;64(11):1774-82. IF: 17.016
  9. Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol. 2018 Jun;68(6):1129-1136. IF: 14.911
  10.  Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. J Hepatol. 2017 Aug;67(2):370-398. IF: 14.911
  11.   Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol. 2016 Apr;64(4):800-6. IF: 14.911
  12.   Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.J Hepatol. 2015 Apr;62(4):956-67. IF: 14.911
  13.   Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.J Hepatol. 2015 Feb;62(2):363-70. IF : 14.911
  14.   Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special Conference.J Hepatol. 2015 Nov;63(5):1238-53. IF: 14.911
  15.   Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.J Hepatol. 2014 Jan;60(1):62-8. IF: 14.911
  16.   Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, Koutsounas S, Vafiadis I, Nikolopoulou G, Giannoulis G, Germanidis G, Papatheodoridis G, Touloumi G Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.J Hepatol. 2013 Nov;59(5):949-56. IF: 14.911
  17.   Papatheodoridis GV, Manolakopoulos S, Su TH, Siakavellas S, Liu CJ, Kourikou A, Yang HC, Kao JH. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.Hepatology. 2017 Aug 31. [Epub ahead of print] IF: 14.079
  18.   Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.Hepatology. 2017 Nov;66(5):1444-1453. IF:14.079
  19.   Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, Petersen J Discontinuation of oral antivirals in chronic hepatitis B: A systematic review.Hepatology. 2016 May;63(5):1481-92. IF:14.079
  20.   Chrysanthos NV, Nezi V, Zafiropoulou R, Papatheodoridis G, Manesis E. Metastatic signet-ring cell carcinoma of the skin.Am J Gastroenterol. 2018 Jun 12. [Epub ahead of print]. IF: 10.231
  21.   Chrysanthos NV, Nezi V, Zafiropoulou R, Papatheodoridis GV, Manesis E Metastatic Signet-Ring Cell Carcinoma of the Skin.Am J Gastroenterol. 2018 Oct;113(10):1427. No abstract available.
  22.   Polymeros D, Tsiamoulos ZP, Koutsoumpas AL, Smyk DS, Mytilinaiou MG, Triantafyllou K, Bogdanos DP, Ladas SD.Bioinformatic and immunological analysis reveals lack of support for measles virus related mimicry in Crohn's disease.BMC Med. 2014 Aug 28;12:139. IF: 9.088
  23.   Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int. 2013 Nov;84(5):880-5. IF: 8.429
  24.   Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M, Castellanos-Fernandez M, George J, Jacobson IM, Bugianesi E, Wong VW, Arrese M, de Ledinghen V, Romero-Gomez M, Mendez-Sanchez N, Ahmed A, Wong R, Papatheodoridis GV, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A; Global NASH Council. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.Clin Gastroenterol Hepatol. 2018 Nov 23. [Epub ahead of print]. IF: 7.896
  25.   Bazerbachi F, Haffar S, Wang Z, Cabezas J, Arias-Loste MT, Crespo J, Darwish-Murad S, Ikram MA, Olynyk JK, Gan E, Petta S, Berzuini A, Prati D, de Lédinghen V, Wong VW, Del Poggio P, Chávez-Tapia NC, Chen YP, Cheng PN, Yuen MF, Das K, Chowdhury A, Caballeria L, Fabrellas N, Ginès P, Kumar M, Sarin SK, Conti F, Andreone P, Sirli R, Cortez-Pinto H, Carvalhana S, Sugihara T, Kim SU, Parikh P, Chayama K, Corpechot C, Kim KM, Papatheodoridis GV, Alsebaey A, Kamath PS, Murad MH, Watt KD. Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals.Clin Gastroenterol Hepatol. 2019 Jan;17(1):54-64.e1. Epub 2018 Sep 7. IF: 7.896
  26.   Younossi ZM, Stepanova M, Younossi I, Pan CQ, Janssen HLA, Papatheodoridis GV, Nader F. Long-Term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes.Clin Gastroenterol Hepatol. 2018 Sep 27. pii: S1542-3565(18)31073-5. [Epub ahead of print]. IF: 7.896
  27.    Karuppuchamy T, Behrens EH, González-Cabrera P, Sarkisyan G, Gima L, Boyer JD, Bamias G, Jedlicka P, Veny M, Clark D, Peach R, Scott F, Rosen H, Rivera-Nieves J. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease.Mucosal Immunol. 2017 Jan;10(1):162-171. IF: 7.360
  28.   Goodman WA, Omenetti S, Date D, Di Martino L, De Salvo C, Kim GD, Chowdhry S, Bamias G, Cominelli F, Pizarro TT, Mahabeleshwar GH. KLF6 contributes to myeloid cell plasticity in the pathogenesis of intestinal inflammation.Mucosal Immunol. 2016 Sep;9(5):1250-62. IF: 7.360
  29.   Chan HLY, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy PT, Thompson A, Caputo A, Bakalos G, Pavlovic V, Lampertico P A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018 Jun 29. [Epub ahead of print]. IF : 7.357
  30.   Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, Petersen J, Lee CM, Ma X, Caruntu FA, Tak WY, Elkhashab M, Lin L, Wu G, Martins EB, Charuworn P, Yee LJ, Lim SG, Foster GR, Fung S, Morano L, Samuel D, Agarwal K, Idilman R, Strasser SI, Buti M, Gaeta GB, Papatheodoridis G, Flisiak R, Chan HL. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.Aliment Pharmacol Ther. 2016 Nov;44(9):957-966. IF: 7.357
  31.   Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.Aliment Pharmacol Ther. 2014 Jan;39(1):35-46. IF: 7.357
  32.   Chan HLY, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy PT, Thompson A, Caputo A, Bakalos G, Pavlovic V, Lampertico P. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B.Aliment Pharmacol Ther. 2018 Sep;48(5):547-555. Epub 2018 Jun 29. IF: 7.357
  33.   Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Latella G.Cellular and Molecular Mediators of Intestinal Fibrosis.J Crohns Colitis. 2017 Dec 4;11(12):1491-1503. IF: 6.637
  34.   Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, Oikonomou KA, Kostas A, Zampeli E, Papadopoulos V, Theodoropoulou A, Viazis N, Polymeros D, Michopoulos S, BamiasG, Kapsoritakis A, Karamanolis DG, Mantzaris GJ, Tzathas C, Koutroubakis IE. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek Patients with Inflammatory Bowel Disease.J Crohns Colitis. 2016 Apr;10(4):429-36. IF: 6.637
  35.   Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis G, Combet E. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.Metabolism. 2018 Jun;83:120-127. IF: 5.963
  36.   Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis.Metabolism. 2017 Mar;68:119-132. IF:5.963
  37.   Karamitros T, Papatheodoridis G, Paraskevis D, Hatzakis A, Mbisa JL, Georgopoulou U, Klenerman P, Magiorkinis G. Impact of interferon-α receptor-1 promoter polymorphisms on the transcriptome of the hepatitis B virus-associated hepatocellular carcinoma.Front Immunol. 2018 Apr 16;9:777. 2018. IF : 5.511
  38.   Borsa D, Kalafati IP, Vlachogiannakos J, Revenas K, Kokkinos A, Ladas S, Dedoussis G. Dietary patterns in NAFLD and their interaction with polymorphisms in PNPLA3 and TM6SF2 genes.Clin Nutr ESPEN. 2018 Apr;24:182. IF: 5.496
  39.   Georgiou A, Vlahogiannakos I, Karagiannakis D, Deutsch M, Alexopoulou A, Ioannidou P, Papageorgiou M, Prapa A, Papatheodoridis G, Kontogianni M. Prevalence of sarcopenia and diagnostic ability assessment of widely available methods of muscle mass and performance estimation in cirrhotic patients.Clin Nutr ESPEN. 2018 Apr;24:185-186. IF: 5.496
  40.   Katsagoni CN, Egkomiti A, Papageorgiou M, Ioannidou P, Fragopoulou E, Papatheodoridis G, Kontogianni M. Improvement in liver function after an intervention based on the Mediterranean diet in patients with non alcoholic fatty liver disease (NAFLD).Clin Nutr ESPEN. 2016 Jun;13:e57. IF: 5.496
  41.   Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, Fragopoulou E, Zafiropoulou R, Manios Y, Papatheodoridis G.Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2014 Aug;33(4):678-83. IF: 5.496
  42.   Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GVTreatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.Br J Haematol. 2017 Jul;178(1):130-136. IF: 5.128
  43.   Bamias G, Filidou E, Goukos D, Valatas V, Arvanitidis K, Panagopoulou M, Kouklakis G, Daikos GL, Ladas SD, Kolios G. Crohn's disease-associated mucosal factors regulate the expression of TNF-like cytokine 1A and its receptors in primary subepithelial intestinal myofibroblasts and intestinal epithelial cells.Transl Res. 2017 Feb;180:118-130. IF: 4.880
  44.   Bamias G, Pizarro TT, Cominelli F. Pathway-based approaches to the treatment of inflammatory bowel disease.Transl Res. 2016 Jan;167(1):104-15. IF: 4.880
  45.   Jia LG, Bamias G, Arseneau KO, Burkly LC, Wang EC, Gruszka D, Pizarro TT, Cominelli F. A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection.J Immunol. 2016 Jul 1;197(1):377-86. IF :4.539
  46.   Vlachogiannakos J, Papatheodoridis GV. Hepatitis B: Who and when to treat?Liver Int. 2018 Feb;38 Suppl 1:71-78. IF: 4.500
  47.   Striki A, Manolakopoulos S, Deutsch M, Kourikou A, Kontos G, Kranidioti H, Hadziyannis E, Papatheodoridis G. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.Liver Int. 2017 Nov;37(11):1642-1650. IF: 4.500
  48.   Vlachogiannakos J, Papatheodoridis GVHBV: Do I treat my immunotolerant patients?Liver Int. 2016 Jan;36 Suppl 1:93-9. IF: 4.500
  49.   Vlachogiannakos J, Papatheodoridis GVOptimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?. Liver Int. 2015 Jan;35 Suppl 1:100-6. IF: 4.500
  50.   Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, Mimidis K, Germanidis G, Drakoulis C, Triantos C, Zintzaras E, Bakalos G, Papatheodoridis G.On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int. 2015 May;35(5):1540-8. IF: 4.500
  51.   Karamitros T, Papatheodoridis G, Dimopoulou E, Papageorgiou MV, Paraskevis D, Magiorkinis G, Sypsa V, Hatzakis A. The interferon receptor-1 promoter polymorphisms affect the outcome of Caucasians with HBeAg-negative chronic HBV infection.Liver Int. 2015 Dec;35(12):2506-13. IF: 4.500
  52.   Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review.Liver Int. 2014 Nov;34(10):1452-63. Epub 2014 May 16. IF: 4.500
  53.   Vlachogiannakos J, Papatheodoridis GV.HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?  Liver Int. 2014 Feb;34 Suppl 1:127-32. IF: 4.500
  54.   Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F.Patient-Reported Outcomes in Patients Chronic Viral Hepatitis without Cirrhosis: The Impact of Hepatitis B and C Viral Replication.Liver Int. 2019 Jun 7. IF: 4.500
  55.   Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F.Patient-Reported Outcomes in Patients Chronic Viral Hepatitis without Cirrhosis: The Impact of Hepatitis B and C Viral Replication.Liver Int. 2019 Jun 7. IF: 4.500
  56.   Georgoulis M, Kontogianni MD, Tileli N, Margariti A, Fragopoulou E, Tiniakos D, Zafiropoulou R, Papatheodoridis G. The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease.Eur J Nutr. 2014 Dec;53(8):1727-35. IF: 4.423
  57.   Kalafati IP, Dimitriou M, Borsa D, Vlachogiannakos J, Revenas K, Kokkinos A, Ladas SD, Dedoussis GV. Fish intake interacts with TM6SF2 gene variant to affect NAFLD risk: results of a case-control study.Eur J Nutr. 2018 Mar 24. [Epub ahead of print] IF: 4.423
  58.   Siakavellas SI, Sfikakis PP, Bamias GThe TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases.Semin Arthritis Rheum. 2015 Aug;45(1):1-8. IF: 4.356
  59.   Siakavellas SI, Bamias G. Tumor necrosis factor-like cytokine TL1A and its receptors DR3 and DcR3: important new factors in mucosal homeostasis and inflammation.Inflamm Bowel Dis. 2015 Oct;21(10):2441-52. IF: 4.347
  60.   Bamias G, Goukos D, Laoudi E, Balla IG, Siakavellas SI, Daikos GL, Ladas SD. Comparative study of candidate housekeeping genes for quantification of target gene messenger RNA expression by real-time PCR in patients with inflammatory bowel disease.Inflamm Bowel Dis. 2013 Dec;19(13):2840-7. IF: 4.347
  61.   Karamanolis GP, Panopoulos S, Denaxas K, Karlaftis A, Zorbala A, Kamberoglou D, Ladas SD, Sfikakis PP.The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial.Arthritis Res Ther. 2016 Sep 1;18:195. IF: 4.269
  62.   Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.J Viral Hepat. 2018 Mar;25 Suppl 1:6-17. IF: 4.237
  63.   Papatheodoridis G, Thomas HC, Golna C, Bernardi M, Carballo M, Cornberg M, Dalekos G, Degertekin B, Dourakis S, Flisiak R, Goldberg D, Gore C, Goulis I, Hadziyannis S, Kalamitsis G, Kanavos P, Kautz A, Koskinas I, Leite BR, Malliori M, Manolakopoulos S, Matičič M, Papaevangelou V, Pirona A, Prati D, Raptopoulou-Gigi M, Reic T, Robaeys G, Schatz E, Souliotis K, Tountas Y, Wiktor S, Wilson D, Yfantopoulos J, Hatzakis A. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. J Viral Hepat. 2016 Feb;23 Suppl 1:1-12. IF: 4.237
  64.   Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Papastergiou V, Thalassinos E, Mantzoukis K, Rodriguez-Peralvarez M, O'Brien J, Noel-Storr A, Papatheodoridis GV, Davidson B, Burroughs AK. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation. J Viral Hepat. 2016 Feb;23(2):139-49. IF: 4.237
  65.   Papatheodoridis G, Triantos C, Hadziyannis E, Zisimopoulos K, Georgiou A, Voulgaris T, Vlachogiannakos I, Nikolopoulou V, Manolakopoulos S. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.J Viral Hepat. 2015 Dec;22(12):1079-87.  IF: 4.237
  66.   Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey.J Viral Hepat. 2015 Apr;22(4):409-15. IF: 4.237
  67.   Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.; HepNet.Greece Study Group. J Viral Hepat. 2015 Feb;22(2):120-7. IF: 4.237
  68.   Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Gadano AC, Gower E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kostrzewska K, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Norris S, Nurmukhametova E, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Schréter I, Shah SR, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Prabdial-Sing N, Flisiak R, Estes C. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.. J Viral Hepat. 2015 Jan;22 Suppl 1:46-73. IF: 4.237
  69.    Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.J Viral Hepat. 2015 Jan;22 Suppl 1:26-45. IF: 4.237
  70.    Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Vree M, Estes C, Flisiak R, Gadano AC, Gane E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, PapatheodoridisG, Pimenov N, Prabdial-Sing N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanduijav R, Schréter I, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Sokolov S, Souliotis K, Spearman CW, Staub T, Strebkova EA, Struck D, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuure FR, Silva MO, Sypsa V, Gower EHistorical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.. J Viral Hepat. 2015 Jan;22 Suppl 1:6-25. IF: 4.237
  71.   Papatheodoridis GV, Manolakopoulos S, Margariti A, Papageorgiou MV, Kranidioti H, Katoglou A, Kontos G, Adamidi S, Kafiri G, Deutsch M, Pectasides D. The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection.J Viral Hepat. 2014 Jul;21(7):517-24. IF: 4.237
  72.   Striki A, Manolakopoulos S, Deutsch M, Mela M, Kalafateli M, Schini M, Anagnostou O, Triantos C, Andreadis I, Ketikoglou I, Papatheodoridis G, Pectasides D. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin.J Viral Hepat. 2014;21(9):624-32. IF: 4.237
  73.    Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S, Dominguez A, Donoghoe M, Elzouki AN, Ben-Alaya Bouafif N, Esmat G, Esteban R, Fabri M, Fenton K, Goldberg D, Goulis I, Hadjichristodoulou C, Hatzigeorgiou T, Hamouda O, Hasurdjiev S, Hughes S, Kautz A, Malik M, Manolakopoulos S, Matičič M, Papatheodoridis G, Peck R, Peterle A, Potamitis G, Prati D, Roudot-Thoraval F, Reic T, Sharara A, Shennak M, Shiha G, Shouval D, Sočan M, Thomas H, Thursz M, Tosti M, Trépo C, Vince A, Vounou E, Wiessing L, Manns M.The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference.J Viral Hepat. 2013 Aug;20 Suppl 2:1-20. IF: 4.237
  74.   Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis. B.J Viral Hepat. 2013 Apr;20(4):e37-46. IF: 4.237
  75.   Papatheodoridi M, Papatheodoridis GV.Can we stop nucleoside analogues before HBsAg loss?J Viral Hepat. 2019 Feb 25. [Epub ahead of print] Review. IF: 4.237
  76.   Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis GV, Khakoo SI. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat. 2019 Jun;26(6):697-709. IF: 4.237
  77.   Wei L, Pavlovic V, Bansal AT, Chen X, Foster GR, He H, Kao JH, Lampertico P, Liaw YF, Motoc A, Papatheodoridis GV, Piratvisuth T, Plesniak R, Wat C.Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.J Viral Hepat. 2019 Apr 10 [Epub ahead of print] IF: 4.237
  78.   Younossi Z, Papatheodoridis GV, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018 Nov;25 Suppl 3:6-14. IF: 4.237
  79.   O'Connor A, Gisbert JP, O'Morain C, Ladas S.Treatment of Helicobacter pylori Infection 2015.Helicobacter. 2015 Sep;20 Suppl 1:54-61. IF: 4.123
  80.   Karagiannakis DS, Vlachogiannakos J, Anastasiadis G,Vafiadis-Zouboulis I, Ladas SD. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis.Hepatol Int. 2014 Oct;8(4):588-94. IF: 4.117
  81.   De Salvo C, Wang XM, Pastorelli L, Mattioli B, Omenetti S, Buela KA, Chowdhry S, Garg RR, Goodman WA, Rodriguez-Palacios A, Smith DE, Abbott DW, Cominelli F, Bamias G, Xin W, Lee JJ, Vecchi M, Pizarro TT. IL-33 drives eosinophil infiltration and pathogenic type 2 helper T-cell immune responses leading to chronic experimental ileitis.Am J Pathol. 2016 Apr;186(4):885-98. IF: 4.069
  82.   Ntziora F, Paraskevis D, Haida C, Manesis E, Papatheodoridis G, Manolakopoulos S, Elefsiniotis I, Karamitros T, Vassilakis A, Hatzakis A. Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine.J Clin Microbiol. 2013 Sep;51(9):2893-900. IF: 4.054
  83.   Triantafyllou K, Kourikou A, Gazouli M, Karamanolis GP, Dimitriadis GD. Functional dyspepsia susceptibility is related to CD14, GNB3, MIF, and TRPV1 gene polymorphisms in the Greek population.Neurogastroenterol Motil. 2017 Jan;29(1). IF: 3.842
  84.   Vanuytsel T, Karamanolis G, Vos R, Van Oudenhove L, Farré R, Tack J. Role of duodenal mucosal nerve endings in the acid-induced duodenogastric sensorimotor reflex: effect of benzocaine in healthy humans.Neurogastroenterol Motil. 2013 May;25(5):e353-61. IF: 3.842
  85.   Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Papageorgiou MV, Fragopoulou E, Kontogianni MD. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.Br J Nutr. 2018 Jul;120(2):164-175. IF: 3.657
  86.   Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Papageorgiou MV, Fragopoulou E, Kontogianni MD. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.Br J Nutr. 2018 Jul;120(2):164-175. IF: 3.657
  87.   Bamias G, Stamatelopoulos K, Zampeli E, Protogerou A, Sigala F, Papamichael C, Christopoulos P, Kitas GD, Sfikakis PP. Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis.Clin Immunol. 2013 May;147(2):144-50. IF: 3.557
  88.   Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.J Gastroenterol Hepatol. 2017 Feb;32(2):466-472. IF: 3.483
  89.   Karamanolis GP, Panopoulos S, Karlaftis A, Denaxas K, Kamberoglou D, Sfikakis PP, Ladas SD. Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study.United European Gastroenterol J. 2015 Jun;3(3):266-71. IF: 3.477
  90.    Karamanolis G, Polymeros D, Triantafyllou K, Adamopoulos A, Barbatzas C, Vafiadis I, Ladas SD. Hiatal hernia predisposes to nocturnal gastro-oesophageal reflux.United European Gastroenterol J. 2013 Jun;1(3):169-74. IF: 3.477
  91.   Karamanolis GP, Panopoulos S, Karlaftis A, Denaxas K, Kamberoglou D, Sfikakis PP, Ladas SD. Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study.United European Gastroenterol J. 2015 Jun;3(3):266-71. IF: 3.477
  92.   Bamias G, Cominelli F Role of type 2 immunity in intestinal inflammation.Curr Opin Gastroenterol. 2015 Nov;31(6):471-6. IF: 3.414
  93.   Bamias G, Arseneau KO, Cominelli F. Cytokines and mucosal immunity.Curr Opin Gastroenterol. 2014 Nov;30(6):547-52. IF: 3.414
  94.   Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Lawrance IC Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.J Crohns Colitis. 2014 Oct;8(10):1147-65. IF: 3.414
  95.   Kostas A,Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.World J Gastroenterol. 2017 Nov 7;23(41):7387-7396. IF: 3.300
  96.   Kourikou A, Karamanolis GP, Dimitriadis GD, Triantafyllou K.  Gene polymorphisms associated with functional dyspepsia.World J Gastroenterol. 2015 Jul 7;21(25):7672-82. IF: 3.300
  97.   Triantos C, Koukias N, Karamanolis G, Thomopoulos K.  Changes in the esophageal mucosa of patients with non erosive reflux disease: How far have we gone?World J Gastroenterol. 2015 May 21;21(19):5762-7. IF: 3.300
  98.   Cholongitas E, Pipili C, Papatheodoridis G.Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. . World J Gastroenterol. 2015 Aug 28;21(32):9526-33. IF: 3.300
  99.   Thomas D, Gazouli M, Karantanos T, Rigoglou S, Karamanolis G, Bramis K, Zografos G, Theodoropoulos GE. Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease.World J Gastroenterol. 2014 Apr 7;20(13):3609-14. IF: 3.300
  100.   Vaiopoulou A, Karamanolis G, Psaltopoulou T, Karatzias G, Gazouli M. Molecular basis of the irritable bowel syndrome.World J Gastroenterol. 2014 Jan 14;20(2):376-83. IF: 3.300
  101.    Cholongitas E, Papatheodoridis GV.Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation.World J Gastroenterol. 2013 Dec 28;19(48):9189-97. IF: 3.300
  102.    Vlachogiannakos J, Papatheodoridis G.Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol. 2013 Dec 21;19(47):8822-30. IF: 3.300
  103.    Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A.Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.World J Gastroenterol. 2019 Mar 21;25(11):1327-1340. IF: 3.300
  104.    Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis.World J Gastroenterol. 2018 Sep 14;24(34):3813-3820. IF: 3.300
  105.    Kaliora AC, Kokkinos A, Diolintzi A, Stoupaki M, Gioxari A, Kanellos PT, Dedoussis GV, Vlachogiannakos J, Revenas C, Ladas SD, Karathanos VT. The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention.Food Funct. 2016 Nov 9;7(11):4533-4544. IF: 3.289
  106.    Zacharopoulou E, Ioakeim S, Tzouvala M, Karamanolis G, Vezakis A, Gazouli M. Correlation of polymorphisms in long non-coding RNAs with the pathogenesis of inflammatory bowel diseases.Dig Liver Dis. 2018 Jun;50(6):624-626. No abstract available. I : 3.287
  107.    Viazis N, Giakoumis M, Bamias G, Goukos D, Koukouratos T, Katopodi K, Karatzas P, Triantos C, Tsolias C, Theocharis G, Daikos GL, Ladas SD, Karamanolis DG, Mantzaris GJ. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.Dig Liver Dis. 2017 Jan;49(1):29-33. IF: 3.287
  108.    Lombardi R, Sambatakou H, Mariolis I, Cokkinos D, Papatheodoridis GV, Tsochatzis EA. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection.Dig Liver Dis. 2016 Dec;48(12):1471-1477. IF: 3.287
  109.    Karamanolis GP, Denaxas K, Panopoulos S, Bournia KV, Zorbala A, Kamberoglou D, Schizas D, Ladas SD, Sfikakis PP. Severe oesophageal disease and its associations with systemic sclerosis.Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):82-85. IF: 3.201
  110.    Bamias G, Clark DJ, Rivera-Nieves J Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets. 2013 Nov;14(12):1490-500. IF: 3.112
  111.    Valatas V, Bamias G, Kolios G. Experimental colitis models: Insights into the pathogenesis of inflammatory bowel disease and translational issues.Eur J Pharmacol. 2015 Jul 15;759:253-64. IF: 3.040
  112.    Tribonias G, Margariti E, Tiniakos D, Pectasides D, Papatheodoridis GV. Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic Fatty liver disease.J Clin Gastroenterol. 2014 Jan;48(1):59-65.  IF: 2.968
  113.    Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV.The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease.J Clin Gastroenterol. 2013 Mar;47(3):280-6. IF: 2.938
  114.    Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.Antivir Ther. 2018 Jul 25. [Epub ahead of print]. IF: 2.910
  115.    Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.Antivir Ther. 2018;23(8):711. IF: 2.910
  116.     Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.Antivir Ther. 2018;23(8):677-685. IF: 2.910
  117.     Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy.Clin Mol Hepatol. 2016 Sep;22(3):319-326. IF: 2.850
  118.     Karagiannakis DS, Papatheodoridis G, Vlachogiannakos J. Recent advances in cirrhotic cardiomyopathy.Dig Dis Sci. 2015 May;60(5):1141-51. IF: 2.819
  119.     Polymeros D, Beintaris I, Gaglia A, Karamanolis G, Papanikolaou IS, Dimitriadis G, Triantafyllou K. Partially hydrolyzed guar gum accelerates colonic transit time and improves symptoms in adults with chronic constipation.Dig Dis Sci. 2014 Sep;59(9):2207-14. IF: 2.819
  120.     Karagiannakis DS, Voulgaris T, Koureta E, Chloupi E, Papatheodoridis GV, Vlachogiannakos J.Role of Spleen Stiffness Measurement by 2D-Shear Wave Elastography in Ruling Out the Presence of High-Risk Varices in Cirrhotic Patients.Dig Dis Sci. 2019 Apr 15. [Epub ahead of print]. . IF: 2.819
  121.    Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis GV, Flisiak R, Chan HLY. Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.Dig Dis Sci. 2019 Jan;64(1):285-286. IF: 2.819
  122.    Gbandi E, Goulas A, Sevastianos V, Hadziyannis S, Panderi A, Koskinas J, Papatheodoridis G, Vasiliadis T, Agapakis D, Protopapas A, Ioannidou P, Zacharakis G, Sinakos E, Koutsounas S, Germanidis G. Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population.Pharmacol Rep. 2016 Apr;68(2):476-82. IF: 2.787
  123.    Vrakas S, Mountzouris KC, Michalopoulos G, Karamanolis G,Papatheodoridis G, Tzathas C, Gazouli M. Intestinal bacteria composition and translocation of bacteria in inflammatory bowel disease.PLoS One. 2017 Jan 18;12(1):e0170034. 2017. IF: 2.766
  124.    Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study GroupAnti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One. 2014 Jul 29;9(7):e101002. 2014. IF: 2.766
  125.    Bamias G, Dahman MI, Arseneau KO, Guanzon M, Gruska D, Pizarro TT, Cominelli F. Intestinal-specific TNFα overexpression induces Crohn's-like ileitis in mice.PLoS One. 2013 Aug 20;8(8):e72594. IF: 2.766
  126.    Georgoulis M, Fragopoulou E, Kontogianni MD, Margariti A, Boulamatsi O, Detopoulou P, Tiniakos D, Zafiropoulou R, Papatheodoridis G.Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity.Nutr Res. 2015 Jan;35(1):41-8. IF: 2.707
  127.    Papaconstantinou I, Zeglinas C, Gazouli M, Nastos K, Yiallourou A, Lykoudis P, Evangelou K, Papalois A, Papaioannou M, Vlachogiannakos J, Tzathas C. Effect of infliximab on the healing of intestinal anastomosis. An experimental study in rats.Int J Surg. 2014;12(9):969-75. IF: 2.693
  128.    Georgoulis M, Kontogianni MD, Margariti A, Tiniakos D, Fragopoulou E, Zafiropoulou R, Papatheodoridis G. Associations between dietary intake and the presence of the metabolic syndrome in patients with non-alcoholic fatty liver disease.J Hum Nutr Diet. 2015 Aug;28(4):409-15. IF: 2.681
  129.    Tsochatzis EA, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK. Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy. Biomed Res Int. 2013;2013:139763. IF: 2.583
  130.    Katsagoni CN, Papatheodoridis GV, Papageorgiou MV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Fragopoulou E, Kontogianni MD. A "healthy diet-optimal sleep" lifestyle pattern is inversely associated with liver stiffness and insulin resistance in patients with nonalcoholic fatty liver disease.Appl Physiol Nutr Metab. 2017 Mar;42(3):250-256. IF: 2.518
  131.    Karagiannakis DS, Voulgaris T, Siakavellas SI, Papatheodoridis GV, Vlachogiannakos J. Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. Scand J Gastroenterol. 2018 Oct - Nov;53(10-11):1153-1164.. Epub 2018 Oct 21. I.F.: 2.329
  132.    Bamias G, Delladetsima I, Perdiki M, Siakavellas SI, Goukos D, Papatheodoridis GV, Daikos GL, Gogas H. Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy.Cancer Invest. 2017 Aug 9;35(7):443-455.  IF: 2.053
  133.    Karamanolis GP, Daikos GL, Xouris D, Goukos D, Delladetsima I, Ladas SD.The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece.Digestion. 2014;90(4):229-31. IF : 2.037
  134.   Papadopoulos N, Deutsch M, Manolakopoulos S, Bitsi C, Michalakeas H, Poulakidas H, Tsironi E, Giannouli S, Papatheodoridis GV, Koskinas J, Pectasides D. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.Eur J Gastroenterol Hepatol. 2017 Jan;29(1):56-60. I.F: 2.014
  135.   Viazis N, Katopodi K, KaramanolisG,DenaxasK, Varytimiadis L, Galanopoulos M, Tsoukali E, KamberoglouD, Christidou A, Karamanolis DG, PapatheodoridisG, Mantzaris GJ. Proton pump inhibitor and selective serotonin reuptake inhibitor therapy for the management of noncardiac chest pain.Eur J Gastroenterol Hepatol. 2017 Sep;29(9):1054-1058. IF: 2.014
  136.    VarbobitisIC, SiakavellasSI, KoutsounasIS, KaragiannakisDS, IoannidouP, PapageorgiouMV, Pavlopoulou ID, Schizas D, BamiasG, VlachogiannakosI, LadasSD, PapatheodoridisGV. Reliability and applicability of two-dimensional shear-wave elastography for the evaluation of liver stiffness.Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1204-9. IF: 2.014
  137.    Margariti A, Kontogianni MD, Tileli N, Georgoulis M, Deutsch M, Zafeiropoulou R, Tiniakos D, Manios Y, Pectasides D, Papatheodoridis GV.Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis.Eur J Gastroenterol Hepatol. 2015 Aug;27(8):907-13. IF: 2.014
  138.    Voulgaris T, Vlachogiannakos J, Ioannidou P, Papageorgiou MV, Zampeli E, Karagiannakis D, Georgiou A, Papazoglou A, Karamanolis G, Papatheodoridis GV. Adherence to follow-up and treatment recommendations in Greek and immigrant patients with chronic hepatitis B in Greece.Eur J Gastroenterol Hepatol. 2017 Mar;29(3):264-270. IF:  2.014
  139.    Ladas SD, Kamberoglou D, Vlachogiannakos J, Tomos P. Combined use of metallic endoclips and endoloops using a single-channel scope in closing iatrogenic perforations and fistulas: two case reports and a literature review.Eur J Gastroenterol Hepatol. 2014 Jan;26(1):119-22. IF: 2.014
  140.    Papadopoulos N, Manolakopoulos S, Deutsch M, Mela M, Christidou A, Katoglou A, Tzourmakliotis D, Papatheodoridis GV. Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece.Eur J Gastroenterol Hepatol. 2013 May;25(5):587-93. IF: 2.014
  141.    Samarkos M, Theofanis V, Eliadi I, Vlachogiannakos J, Polyzos A. Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B. J Gastrointestin Liver Dis. 2014 Sep;23(3):342. No abstract available. IF: 1.964
  142.    Galanopoulos M, Papanikolaou IS, Zografos E, Viazis N, Papatheodoridis G, Karamanolis D, Marinos E, Mantzaris GJ, Gazouli M. Comparative study of mutations in single nucleotide polymorphism loci of KRAS and BRAF genes in patients who underwent screening colonoscopy, with and without premalignant intestinal polyps.Anticancer Res. 2017 Feb;37(2):651-657. IF: 1.865
  143.   Triantafyllou K, Sioulas AD, Kalli T, Misailidis N, Polymeros D, Papanikolaou IS, Karamanolis G, Ladas SD.Optimized sedation improves colonoscopy quality long-term.Gastroenterol Res Pract. 2015;2015:195093. IF: 1.859
  144.    Triantafyllou K, Sioulas AD, Kalli T, Misailidis N, Polymeros D, Papanikolaou IS, Karamanolis G, Ladas SD. Optimized sedation improves colonoscopy quality long-term.Gastroenterol Res Pract. 2015;2015:195093. IF: 1.859
  145.    Katsagoni CN, Georgoulis M, Papatheodoridis GV, Fragopoulou E, Ioannidou P, Papageorgiou M, Alexopoulou A, Papadopoulos N, Deutsch M, Kontogianni MD. Associations between lifestyle characteristics and the presence of nonalcoholic fatty liver disease: a case-control study.Metab Syndr Relat Disord. 2017 Mar;15(2):72-79. IF: 1.744
  146.    Bamias G, Gizis M, Delladetsima I, Laoudi E,Siakavellas SI, Koutsounas I, Kaltsa G, Vlachogiannakos J, Vafiadis-Zouboulis I, Daikos GL, Papatheodoridis GV, Ladas SD. Elevated serum levels of the antiapoptotic protein decoy-receptor 3 are associated with advanced liver disease.Can J Gastroenterol Hepatol. 2016;2016:2637010. IF: 1.622
  147.    Mantas D, Damaskos C, Bamias G, Dimitroulis D. Colonic casts: unexpected complications of colonic ischaemia.Ann R Coll Surg Engl. 2016 Sep;98(7):e109-10. IF: 1.470
  148.    Perdiki M, Karamanolis G, Varbobitis I, Kavoura E, Delladetsima I. Is there a correlation between autoimmune and alkaline gastritis?Pol J Pathol. 2017;68(1):73-74. No abstract available. IF: 0.865
  149.    Tsoucalas G, Papaioannou TG, Papatheodoridis GV, Karamanou M. Hippocratic views in the treatment of rectal prolapse.Acta Gastroenterol Belg. 2017 Jul-Sep;80(3):411-415. IF: 0.630
  150.    Vasiliou C, Xiromeritou V, Kafiri G, Papatheodoridis G. Endoscopic and histological findings and Helicobacter pylori status in patients with reflux and/or dyspeptic symptoms: a recent Greek cohort study.Gastroenterol Nurs. 2014 Nov-Dec;37(6):431-8. IF: 0.577
  151.   Polaris Observatory Collaborators (196 collaborators including Papatheodoridis G). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. IF: -
  152.    Polaris Observatory HCV Collaborators (222 collaborators including Papatheodoridis G). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. IF: -
  153.    European Union HCV Collaborators (115 collaborators including Papatheodoridis G). Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.Lancet Gastroenterol Hepatol. 2017 May;2(5):325-336. IF: -
  154.    Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.Lancet Gastroenterol Hepatol. 2016 Sep;1(1):25-35. IF: -
  155.    Zampeli E, Gizis M, Siakavellas SI, Bamias G. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis.World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):293-303. IF: -
  156.    Cholongitas E, Pipili C, Papatheodoridis GV.Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation. World J Hepatol. 2017 Feb 8;9(4):180-190. IF: -
  157.    Koutsounas I, Kaltsa G, Siakavellas SI, Bamias G. Markers of bacterial translocation in end-stage liver disease.World J Hepatol. 2015 Sep 18;7(20):2264-73. IF: -
  158.    Triantafyllou K, Papadopoulos V, Emanouil T, Gkolfakis P, Damaskou V, Tziatzios G, Panayiotides IG, Vafiadis I, Ladas SD.Eradication of Helicobacter pylori infection restores ki67, p53, and cyclin D1 immunoreactivity in the human gastric epithelium.. Clin Med Insights Gastroenterol. 2016 Nov 17;9:73-78. IF: -
  159.    Papadopoulos N, Papavdi M, Pavlidou A, Konstantinou D, Kranidioti H, Kontos G, Koskinas J, Papatheodoridis GV, Manolakopoulos S, Deutsch M Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues.Ann Gastroenterol. 2018 May-Jun;31(3):365-370. IF: -
  160.    Denaxas K,Ladas SD, Karamanolis GP.Evaluation and management of esophageal manifestations in systemic sclerosis. Ann Gastroenterol. 2018 Mar-Apr;31(2):165-170. IF: -
  161.    Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review.Ann Gastroenterol. 2018 Jul-Aug;31(4):480-490. IF: -
  162.    Papatheodoridi Μ, Dalekos GN, Goulis J, Manolakopoulos S, Triantos C, Zachou K, Koukoufiki A, Κourikou Α, Ζisimopoulos Κ, Τsoulas C, Papatheodoridis GVPrioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice.Ann Gastroenterol. 2017;30(5):542-549. IF: -
  163.    Papageorgiou MV, Hadziyannis E, Tiniakos D, Georgiou A, Margariti A, Kostas A,Papatheodoridis GV.Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Ann Gastroenterol. 2017;30(2):209-216. IF: -
  164.   Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S; PegBase Group Investigators. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.Ann Gastroenterol. 2017;30(3):327-343 IF: -
  165.   KaltsaG, BamiasG, SiakavellasSI, Goukos D, KaragiannakisD, Zampeli E, VlachogiannakosJ, Michopoulos S, VafiadiI, Daikos GL, LadasSD.Systemic levels of human β-defensin 1 are elevated in patients with cirrhosis. Ann Gastroenterol. 2016 Jan-Mar;29(1):63-70. IF: -
  166.    Kotsiri I, Hadziyannis E, Georgiou A, Papageorgiou MV,Vlachogiannakos I,Papatheodoridis G. Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy.  Ann Gastroenterol. 2016 Jan-Mar;29(1):79-84. IF: -
  167.    Kanellopoulou T, Alexopoulou A, Kontopidou FN, Konstantinides P, Papatheodoridis GV.The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking. Ann Gastroenterol. 2016 Apr-Jun;29(2):201-7. IF: -
  168.    Mantzaris GJ, Viazis N, Polymeros D, Papamichael K, Bamias G, Koutroubakis IE Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol. 2015 Oct-Dec;28(4):417-25. IF: -
  169.   Manolakopoulos S, Kranidioti H, Goulis J, Vlachogiannakos J, Elefsiniotis J, Kouroumalis EA, Koskinas J, Kontos G, Evangelidou E, Doumba P, Sinakos E, Vafiadou Ι, Koulentaki M, Papatheodoridis G, Akriviadis E. Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience.Ann Gastroenterol. 2015 Oct-Dec;28(4):481-6. IF: -
  170.   Cholongitas E, Papatheodoridis GV, Goulis J, Vlachogiannakos J, Karatapanis S, Ketikoglou J, Vasiliadis T, Kontos G, Karlaftis A, Akriviadis E. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis.. Ann Gastroenterol. 2015 Jan-Mar;28(1):109-117. IF: -
  171.   Cholongitas E, Papatheodoridis GV. Sofosbuvir: a novel oral agent for chronic hepatitis C.Ann Gastroenterol. 2014;27(4):331-337. IF: -
  172.   Konstantinou D, Margariti E, Hadziyannis E, Pectasides D, Papatheodoridis GV.Significance of the 13C-caffeine breath test for patients with cirrhosis.Ann Gastroenterol. 2014;27(1):53-59. IF: -
  173.   Rossolymos NA, Papatheodoridis G, Tsakoniatis M, Konstantinou D, Lazaris A. Expression of cyclooxygenase-2 in gastritis and gastric premalignant lesions.Ann Gastroenterol. 2013;26(3):275. No abstract available. IF: -
  174.    Dalekos GN, Koskinas J, Papatheodoridis GV.Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis.Ann Gastroenterol. 2019 Jan-Feb;32(1):1-23. IF: -
  175.   Lampertico P, Messinger D, Cornberg M, Brunetto M, Petersen J, Kennedy P, Asselah T, Rothe V, Caputo A, Bakalos G, Pavlovic V, Papatheodoridis GV. A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B.Ann Gastroenterol. 2018 Nov-Dec;31(6):712-721. Epub 2018 J. IF: -
  176.     Kranidioti H, Chatzievagelinou C, Protopapas A, Papatheodoridi M, Zisimopoulos K, Evangelidou E, Antonakaki P, Vlachogiannakos J, Triantos C, Elefsiniotis I, Goulis J, Mela M, Anagnostou O, Tsoulas C, Deutsch M, Papatheodoridis GV, Manolakopoulos S. Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis.  Ann Gastroenterol. 2018 Sep-Oct;31(5):598-603. Epub 2018 Jul 19. IF: -
  177.   Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review.Ann Gastroenterol. 2018 Jul-Aug;31(4):480-490. Epub 2018 Apr 28.
  178.    Vourli G, Papatheodoridis G, Raptopoulou M, Dalekos GN, Hounta A, Nikolopoulou G, Zouboulis-Vafeiadis I, Manesis E, Kitis G, Gogos C, Ketikoglou I, Hatzis G, Vasilialdis T, Karatapanis S, Mimidis K, Drakoulis C, Touloumi G The Hepnet-Greece, Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study. Hippokratia. 2016 Jul-Sep;20(3):214-221. IF: -
  179.    Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou-Gigi M, Manesis E, Ketikoglou I, Dalekos G, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zouboulis-Vafeiadis I, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.Hippokratia. 2014 Jan;18(1):57-64. IF: -
  180.    Panagiotopoulos P, Maniadakis N, Papatheodoridis G, Pektasidis D An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals.Pharmacoecon Open. 2019 May 20. [Epub ahead of print]. IF: -